These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35383116)

  • 1. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.
    Cui C; Wang X; Lian B; Ji Q; Zhou L; Chi Z; Si L; Sheng X; Kong Y; Yu J; Li S; Mao L; Tang B; Dai J; Yan X; Bai X; Andtbacka R; Guo J
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.
    Beasley GM; Nair SK; Farrow NE; Landa K; Selim MA; Wiggs CA; Jung SH; Bigner DD; True Kelly A; Gromeier M; Salama AK
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33875611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.
    Wang C; Lu N; Yan L; Li Y
    Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
    Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
    Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
    Senzer NN; Kaufman HL; Amatruda T; Nemunaitis M; Reid T; Daniels G; Gonzalez R; Glaspy J; Whitman E; Harrington K; Goldsweig H; Marshall T; Love C; Coffin R; Nemunaitis JJ
    J Clin Oncol; 2009 Dec; 27(34):5763-71. PubMed ID: 19884534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
    Curti BD; Richards J; Hyngstrom JR; Daniels GA; Faries M; Feun L; Margolin KA; Hallmeyer S; Grose M; Zhang Y; Li A; Andtbacka RHI
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
    J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
    Chesney JA; Puzanov I; Collichio FA; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan T; Hauschild A; Lebbé C; Joshi H; Snyder W; Mehnert JM
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
    Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral administration of CD1c (BDCA-1)
    Schwarze JK; Tijtgat J; Awada G; Cras L; Vasaturo A; Bagnall C; Forsyth R; Dufait I; Tuyaerts S; Van Riet I; Neyns B
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.
    Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S
    Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
    Smith KER; Peng KW; Pulido JS; Weisbrod AJ; Strand CA; Allred JB; Newsom AN; Zhang L; Packiriswamy N; Kottke T; Tonne JM; Moore M; Montane HN; Kottschade LA; McWilliams RR; Dudek AZ; Yan Y; Dimou A; Markovic SN; Federspiel MJ; Vile RG; Dronca RS; Block MS
    Front Immunol; 2023; 14():1279387. PubMed ID: 38022659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus oncolytic vaccine therapy in melanoma.
    Sivendran S; Pan M; Kaufman HL; Saenger Y
    Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.